Press releases

28 Jun 2024

Acquisition of own shares

28 Jun 2024

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

26 Jun 2024

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

14 Jun 2024

Acquisition of own shares

13 Jun 2024

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

12 Jun 2024

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Press releases

Press releases

Search Press releases

Acquisition of own shares

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Acquisition of own shares

UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)

UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures

Acquisition of own shares

New data support the value of CIMZIA[®] for women living with chronic rheumatic diseases throughout pregnancy and post-partum, and for people living with RA and high rheumatoid factor levels

UCB to share first presentations of BIMZELX[®]▼ (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Choose a Country